On Demand 2016 Friday General Sessions

You can earn up to 15 AMA PRA Category 1 Credit(s)™.

This collection covers general sessions from Friday's program. This includes plenaries, symposia, and workshops. The sessions listed below are included in this package:

  • The Use of Biologics in Severe Asthma
  • W4 - When Cough, Wheeze or Dyspnea Are Not Asthma
  • Diagnosis and Treatment of Primary Immune Deficiency
  • W6 - Office Procedures for Allergic Skin Diseases
  • Pro/Con: The LEAP Study Results Should Be Applied to Foods Other Than Peanuts
  • W3 - Food Challenges in Practice: Safe and Simplified
  • W5 - Drug Allergy Options Beyond Avoidance: Where the Allergist Matters
  • Leading the Pack: Allergists as Anaphylaxis Experts
  • W1 - Insect Allergy Update

Release Date: 12/01/2016
Expiration Date: 11/30/2019

Accreditation

The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 15 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Learning Objectives

  • Discuss the biologic mechanisms underlying asthma and which are targets for biologic therapy
  • Describe the characteristics of patients who would be candidates for the newly approved biologic therapies for asthma
  • Discuss the biology of asthma and which new inflammatory mediators are candidates for new biologic therapies
  • Identify the clinical characteristics that support asthma as the cause of cough, wheeze, or dyspnea
  • Recognize that not all coughs or wheezes are asthma
  • Differentiate symptoms common for asthma from other causes of those symptoms
  • Discuss the use of hematopoietic cell transplantation for primary immune deficiencies
  • Describe the current status of newborn screening for severe combined immune deficiency and its impact on patient care
  • Discuss advances in gene therapy to treat combined immune deficiency
  • Utilize guideline-based clinical criteria and testing for the accurate diagnosis of patients with HAE
  • Review the underlying enzymatic pathways involved in the pathogenesis of HAE
  • Describe therapies available for on-demand treatment of an HAE attack and for short- and long-term prophylaxis in selected patients
  • Describe the different tests for physical urticarial and the indications for skin biopsy and interpretation of skin biopsy results
  • Discuss the indications and interpretation of the standard epicutaneous patch testing and the utility of repeat open application testing
  • Demonstrate the application of epicutaneous patch testing
  • Recommend early feeding practices for infants at risk for development of food allergy
  • Recognize current evidence and knowledge gaps regarding primary prevention of food allergy
  • Describe how to perform an oral food challenge
  • Review indications for an oral food challenge and reasons for deferment
  • Discuss diagnostic tests and management options for patients with reported hypersensitivity to antibiotics, including beta-lactams, macrolides, quinolones and sulfonamides
  • Discuss diagnostic tests and management options for patients with reported hypersensitivity to aspirin and NSAIDs
  • Discuss diagnostic tests and management options for patients with reported hypersensitivity to chemotherapeutic drugs
  • Demonstrate competence in allergen selection and administration in successful cluster and rush immunotherapy regimens
  • identify patient indications, immunologic mechanisms, and special considerations related to cluster and rush immunotherapy delivery
  • Describe minimum equipment needed in an allergist’s office to manage anaphylactic reactions when they occur
  • Consider using a patient-oriented anaphylaxis preparedness questionnaire as an educational tool for patients at risk of anaphylaxis
  • Discuss the pros and cons of available anaphylaxis outpatient action plans and describe in general terms the current state of the literature with respect to biphasic reactions in terms of incidence rates and predictors
  • Recognize the most common insects that cause reaction in humans, as well as the reactions these insects cause
  • Develop an evaluation and treatment plan, as well as evaluate how to work with local emergency departments for aftercare of patients seen
  • Review management of insect allergy with emphasis on the What’s New section of the upcoming Insect PP
Additional information
Disclosure: 

Alan B. Goldsobel, MD, FACAAI -- Speaker: Meda, Mylan, Teva; Supported/Contracted Research: AstraZeneca, Novartis, Sanofi, Stallergenes, Teva

Mario Castro, MD, MPH -- Consultant/Advisor: Boston Scientific, Genentech, GlaxoSmithKline, Neostem, Holaira, Sparo, INC, Teva; Speaker: Boehringer Ingelheim, Boston Scientific, Genentech, Teva; Supported/Contracted Research: Amgen, Boehringer Ingelheim, Genentech, GlaxoSmithKline, Johnson & Johnson, MedImmune, Novartis, Pfizer, Sanofi, Teva, Vectura

Prescott Woodruff, MD -- Consultant/Advisor: Amgen, AstraZeneca, Janssen, Novartis, Roche, Sanofi; Supported/Contracted Research: Genentech, MedImmune, Pfizer

Larry Borish, MD, FACAAI -- Consultant/Advisor: Novartis, Allakos, PluriStem, Teva

Rohit K. Katial, MD, FACAAI -- Consultant/Advisor: AstraZeneca, Meda, Teva; Speaker: Meda, Teva

John M. Routes, MD, FACAAI -- Speaker: CSL Behring

Morton J. Cowan, MD -- Consultant/Advisor: Homology Medicine, Exogen Bio; Speaker: Homology Medicine, Exogen Bio

Jennifer Puck, MD -- Employee: Invitae (spouse); Ownership Interest: Invitae (spouse is employee)

Michael E. Manning, MD, FACAAI -- Consultant/Advisor: CSL Behring, Dyax, Genentech, Shire

Bruce L. Zuraw, MD, FACAAI -- Consultant/Advisor: Biocryst, Novartis, CSL Behring, Sanofi, Shire, Dyax, Genentech, Alnylan, Arrowhead, Isis

Marc A. Riedl, MD, MS -- Consultant/Advisor: Baxter, Biocryst, CSL Behring, Grifols, Arrowhead, Ionis, Salix, Shire; Speaker: Baxter, CSL Behring, Dyax, Salix, Shire; Supported/ Contracted Research: Amgen, Biocryst, CSL Behring, Dyax, Ionis, Pharming, Shire

Joshua S. Jacobs, MD -- Supported/Contracted Research: AstraZeneca, Biocryst, Circassia, CSL Behring, Dyax, Genentech, Merck, Novartis, Roche, Shire, Teva; Consultant/Advisor: Dyax, Novartis, Roche, Salix, Shire, Teva, Valeant; Speaker: Dyax, Merch, Novartis, Shire, Teva

Luz S. Fonacier, MD, FACAAI -- Consultant/Advisor: Regeneron, Church and Dwight; Speaker: Baxter; Supported/Contracted Research:Baxter, Genentech, Merck

Sharon E. Jacob, MD -- Consultant: Johnson and Johnson, Skintifique; Speaker & Independent Investigator- Smartpractice, USA (makers TRUE Test); Founder-CEO, Dermatitis Academy, free educational online resource

Trever Burnett, MD -- Speaker: Teva

Rima A. Rachid, MD -- Consultant/Advisor: Aimmune Therapeutics; Supported/Contracted Research: Aimmune Therapeutics

Hugh A. Sampson, MD, FACAAI -- Consultant/Advisor: Allertein, Danone Scientific Advisory Board, DBV Technologies, Herbs Spring, LLC, Thermo Fisher Scientific; Patent Holder/Royalty/IPR: Herbs Spring, LLC

David B. Engler, MD, FACAAI -- Speaker: Boehringer Ingelheim; Consultant/Advisor: Gilead, Regeneron

Mike Tankersley, MD, FACAAI -- Speaker: Merck

Anne K. Ellis, MD, MSc, FACAAI -- Consultant/Advisor: ALK, Circassia, GlaxoSmithKline, Merck, Novartis, ALK–Abello, IncALK–Abello, Ora, Inc, Ora, Ora, Inc,  Pfizer, Teva; Speaker: AstraZeneca, Circassia, Merck, Novartis, Ora, Ora, Inc, Pfizer; Supported/ Contracted Research: Circassia, GlaxoSmithKline, Merck, Novartis, Pfizer

Dana V. Wallace, MD, FACAAI -- Consultant/Advisor: Mylan, Kaleo

Stanley M. Fineman, MD, MBA, FACAAI -- Consultant/Advisor: Aimmune; Speaker: AstraZeneca, Boehringer Ingelheim, Genentech, Greer, Meda, Novartis, Nestle, Teva; Supported/Contracted Research: DBV Technologies, Genentech, Greer, Meda, Aimmune, Stallergenes

James M. Tracy, DO, FACAAI -- Consultant/Advisor: Shire; Speaker: UptoDate

The following have no financial relationships to disclose:

Stephen C. Lazarus, MD

Maria G. Roncarolo, MD

Katrina Allen, MD, PhD

Amal H. Assa’ad, MD, FACAAI

Aleena Banerji, MD

Roland Solensky, MD, FACAAI

Theodore M. Freeman, MD, FACAAI

Course summary
Available credit: 
  • 15.00 AMA PRA Category 1 Credit™
  • 15.00 Attendance
Course opens: 
11/30/2016
Course expires: 
11/30/2019
Cost:
$0.00
Rating: 
0

Available Credit

  • 15.00 AMA PRA Category 1 Credit™
  • 15.00 Attendance

Accreditation Period

Course opens: 
11/30/2016
Course expires: 
11/30/2019

Price

Cost:
$0.00
Please login or create an account to take this course.